Imagine if you could find a dangerous polyp or cancer in your gut with a simple blood draw instead of a colonoscopy. This technology looks for specific biological markers in the blood and combines them with your lifestyle data using AI. It acts like an early warning system, spotting risks years before symptoms appear, even in people under 50.
Colorectal cancer has a 48% mortality rate, yet only 10% of the eligible EU population undergoes screening due to the invasive nature of colonoscopies. There is a critical need for a non-invasive, cost-effective test that improves patient compliance and detects cancer in younger populations.
A non-invasive blood test (PreveCol™) combining molecular biomarkers with an AI-driven risk factor algorithm to detect colorectal cancer and advanced adenomas.
If you are a diagnostic laboratory dealing with low patient compliance for invasive screenings — this project developed PreveCol™ that provides a non-invasive blood-based alternative. This increases the number of people screened and improves early detection rates. It can be sold as a Laboratory Developed Test (LDT) or an IVD kit.
If you are a national health provider dealing with high costs of late-stage cancer treatment — this project developed a screening tool that identifies cancer and advanced adenomas early. This reduces the need for expensive invasive procedures and lowers overall healthcare spending. It targets the 90% of the eligible EU population currently not screened.
If you are a health tech company dealing with imprecise age-based screening criteria — this project developed an AI and Big Data algorithm that identifies risk factors beyond age. This allows for personalized screening programs based on individual clinical records. It enables the identification of high-risk patients even under age 50.
AMADIX expects to reach accumulated revenues of €1,997M between 2023-2032 from commercialization in Europe and the USA.
The project aims to commercialize PreveCol™ as both a Laboratory Developed Test (LDT) and as an In Vitro Diagnostic (IVD) kit.
Based on available project data, the technology is developed by AMADIX (Advanced Marker Discovery SL) for commercialization as a proprietary diagnostic test (PreveCol™).
The project period is from 2022-08-01 to 2025-03-31.
It serves as a non-invasive alternative or precursor to colonoscopy, which is currently the gold standard but is invasive and expensive.
The project is led by a single Spanish SME, Advanced Marker Discovery SL (AMADIX). With a 100% industry ratio and no university or research partners, the project is lean and focused entirely on commercialization and market entry rather than basic research.
Contact Rocío Arroyo at Advanced Marker Discovery SL
Contact us to explore licensing opportunities for AI-driven liquid biopsy tools.
